id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-P-0006-0006,FDA,FDA-2006-P-0006,Citizen Petition from AAC Consulting Group,Other,Citizen Petition,2008-08-12T04:00:00Z,2008,8,2008-08-12T04:00:00Z,,2024-11-14T14:48:47Z,,1,0,090000648044143d
FDA-2006-P-0006-0005,FDA,FDA-2006-P-0006,Letter from FDA CDER to AAC Consulting Group/Kendle,Other,Letter(s),2007-11-30T05:00:00Z,2007,11,,,2024-11-14T14:39:25Z,,0,0,0900006480441445
FDA-2006-P-0006-0004,FDA,FDA-2006-P-0006,"Determination That ELOXATIN (Oxaliplatin for Injection), 50 and 100
Milligrams Per Vial, Sterile Lyophilized Powder for Injection, Was Not
Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,N-Notice,2007-11-27T05:00:00Z,2007,11,2007-11-23T05:00:00Z,,2024-11-14T14:37:17Z,,0,0,0900006480441444
FDA-2006-P-0006-0003,FDA,FDA-2006-P-0006,Letter from FDA CDER to AAC Consulting Group,Other,Letter(s),2007-01-23T05:00:00Z,2007,1,,,2024-11-14T14:36:39Z,,0,0,0900006480441443
FDA-2006-P-0006-0002,FDA,FDA-2006-P-0006,Acknowledgment Letter from FDA DMB to AAC Consulting Group,Other,Acknowledgement Letter/Receipt,2006-07-25T04:00:00Z,2006,7,,,2024-11-14T14:31:40Z,,0,0,090000648044143f
FDA-2006-P-0006-0001,FDA,FDA-2006-P-0006,Acknowledgment Letter from FDA DMB to AAC Consulting Group,Other,Acknowledgement Letter/Receipt,2006-07-25T04:00:00Z,2006,7,,,2024-11-14T14:22:37Z,,0,0,090000648044143a